In this issue of the journal, Yogendrakumar and colleagues presented a timely and informative international survey of clinician practices and contemporary perspectives regarding atrial fibrillation (AF) monitoring and rhythm management post-stroke.^{Reference Yogendrakumar, Ayan and Field1} The authors highlighted substantial heterogeneity in post-stroke monitoring, with prolonged monitoring (7+ days) performed in just over half of patients (57%) with embolic stroke of undetermined source. Furthermore, only 49% of respondents were aware of EAST-AFNET 4, underscoring the need for improved dissemination and uptake of key trial data.^{Reference Kirchhof, Camm and Goette2} The broad participation of over 240 clinicians across diverse regions and specialties provided valuable insight into the real-world variability and ongoing clinical equipoise in various aspects of AF management.

The authors surveyed clinicians on the duration of AF paroxysms that should prompt notification, to which there were varying responses ranging from 30 minutes to 24 hours of AF. These findings highlight inconsistencies in the minimum duration of AF for clinical and subclinical AF. While most post-stroke studies will define AF as a 30-second episode detected on monitoring (“clinical AF”),^{Reference Gladstone, Spring and Dorian3,Reference Sanna, Diener and Passman4} there is literature to support differing thresholds in patients with “subclinical AF.” Subclinical AF refers to atrial high-rate episodes detected using a pacemaker, defibrillator or implantable loop recorder in asymptomatic patients with no history of AF. The threshold duration for subclinical AF diagnosis is longer (5–6 minutes rather than 30 seconds) due to the duration required for confirmatory algorithms through the device and the stochastic nature of the diagnosis. Furthermore, the threshold for anticoagulation is an area of active investigation, with studies demonstrating a benefit in those with episodes > 24 hours and risk-benefit discussion in those with episodes shorter than 24 hours.^{Reference Healey, Lopes and Granger5,Reference Lopes, Heizer and Aronson6}

The authors also observed general interest in pursuing rhythm control in patients with acute stroke and AF. When respondents were presented with the main results from the EAST-AFNET 4 trial, the majority expressed equipoise in the benefit of rhythm control in the post-stroke population. The EAST-AFNET 4 trial demonstrated improved cardiovascular outcomes (reduced death, stroke, cardiovascular hospitalization) with early rhythm control of AF,^{Reference Kirchhof, Camm and Goette2} and there is great interest to explore whether these findings may selectively benefit high-risk subgroups such as post-stroke patients. Further inquiry into regional variations in rhythm control practices across geographies would be of great interest.

Overall, Yogendrakumar and colleagues provided a valuable contribution that sheds light on global practice patterns and research priorities in post-stroke AF management. These findings demonstrated general equipoise in the field and will undoubtedly serve as the foundation for prospective studies in both AF monitoring and treatment in this high-risk population.